REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

06 Apr 2023 07:00:54 By Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

07 Mar 2023 16:02:17 By Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

02 Mar 2023 21:15:55 By Nasdaq GlobeNewswire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

01 Mar 2023 16:17:35 By Nasdaq GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

27 Feb 2023 16:05:07 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

21 Feb 2023 16:05:16 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

02 Feb 2023 07:00:12 By Nasdaq GlobeNewswire

Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor

19 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

07 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

09 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

07 Nov 2022 16:05:02 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

01 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

22 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

01 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

31 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

09 Aug 2022 16:02:00 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

28 Jul 2022 16:02:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

22 Jul 2022 16:02:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

19 Jul 2022 22:41:52 By Nasdaq GlobeNewswire